Quantity of eligible individuals: CDEC mentioned the uncertainty in the amount of patients with reasonably significant to severe hemophilia B in Canada suitable for etranacogene dezaparvovec. Scientific industry experts consulted by CADTH indicated that some people who will be labeled as obtaining g